Why these conditions are grouped together
The conditions covered on this page all share three things: they are inherited (usually in an autosomal dominant pattern), they affect the electrical system rather than the heart’s structure, and they can produce sudden, dangerous rhythms in patients whose hearts otherwise look completely normal. They are sometimes called channelopathies because they involve the ion channels that move charged particles in and out of heart cells — the molecular machinery that makes the heart beat.
For a long time these conditions were diagnosed only after a catastrophic event. Modern ECG, genetics, and family screening have shifted the landscape: we now diagnose many patients before any symptoms, treat them prophylactically, and screen their families.
The four most clinically important channelopathies have individual deep-dive pages — this page exists to orient you to the group as a whole and help you decide which deep dive to read next.
Long QT Syndrome (LQTS)
The QT interval on the ECG measures how long it takes the ventricles to electrically reset between beats. In long QT syndrome, that interval is prolonged because the potassium channels that drive repolarization don’t work normally. The prolonged reset creates a window during which an extra beat can trigger a dangerous spiraling rhythm called torsades de pointes.
LQTS affects roughly 1 in 2,000 people. Most are asymptomatic until something — exercise (LQT1), emotional stress (LQT2), or sleep (LQT3) — triggers an event. Beta-blockers, avoidance of QT-prolonging medications, and sometimes an ICD are the cornerstones of treatment.
See the full Long QT syndrome page for symptoms, ECG findings, genetic subtypes, and treatment in detail.
Brugada Syndrome
Brugada syndrome involves the sodium channels that initiate each heartbeat. The abnormality produces a characteristic ECG pattern in leads V1–V2 (a coved or saddleback ST elevation pattern), and predisposes patients to ventricular fibrillation — often during sleep, often in young men, often without warning.
Brugada is genetically heterogeneous (more than 20 implicated genes; SCN5A is the most common) and clinically heterogeneous. Some patients have the ECG pattern but never have an event. Some have a single dramatic event as the first manifestation. Risk stratification is one of the most actively studied questions in EP.
Treatment is mainly an ICD in the appropriate-risk patient. Avoidance of certain medications (sodium-channel blockers, some antidepressants, certain anesthetics), avoidance of high fever, and management of fevers when they happen are also important.
See the full Brugada syndrome page for the ECG patterns, risk factors, and detailed management.
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
CPVT is the only one of the channelopathies whose resting ECG is typically completely normal. The abnormality involves calcium handling inside the heart cells; under adrenergic stress — exercise, intense emotion, sometimes IV catecholamines — the cells become electrically unstable and a fast, polymorphic ventricular tachycardia ensues.
The classic presentation is exercise-induced syncope or sudden death in a child or young adult, often with a family history of similar events. Exercise testing reproduces the arrhythmia and is the central diagnostic step.
Treatment includes high-dose beta-blockers (often nadolol), avoidance of strenuous competitive sports, an ICD in higher-risk patients, and sometimes left cardiac sympathetic denervation for refractory cases.
Short QT Syndrome
The mirror image of long QT — a QT interval that is too short, predisposing to atrial and ventricular arrhythmias. Much rarer than long QT (only a few hundred cases reported worldwide). Treatment is usually an ICD when documented, and avoidance of medications that further shorten the QT.
What about HCM, ARVC, and inherited cardiomyopathies?
These are inherited conditions that affect the heart’s structure primarily, with arrhythmic consequences. They live in a related but distinct category. The site has separate pages for them:
- Hypertrophic cardiomyopathy — thickening of the heart muscle, particularly the septum
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) — covered in the idiopathic VT page and in the VT page broadly
- Familial dilated cardiomyopathy — covered in the heart-failure pages
The principles overlap (genetic, family screening, ICD consideration) but the diagnostic and treatment approaches differ enough that we keep them separate.
How we make the diagnosis
The workup is similar across the channelopathies and proceeds in steps:
- Personal history — syncope, near-syncope, palpitations, especially with specific triggers (exercise, emotional stress, sleep, fever, certain medications)
- Family history — sudden cardiac death (especially before age 50), unexplained drowning, sudden infant death, unexplained car crashes in young drivers
- Resting 12-lead ECG — looking for the specific signatures (long QT, Brugada pattern, T-wave abnormalities)
- Provocative testing when needed:
- Exercise testing for LQT1 and CPVT
- Ajmaline or procainamide challenge for Brugada (under controlled conditions)
- Genetic testing — increasingly first-line when family history is suggestive
- Echocardiogram and cardiac MRI to confirm a structurally normal heart and rule out the cardiomyopathies
The order can vary. In a patient with a strong family history of sudden death and a normal ECG, we sometimes go straight to genetic testing.
Treatment principles, common across these conditions
- Beta-blockers are the foundation in LQTS, CPVT, and some forms of Brugada. Compliance is critical and often lifelong.
- Trigger avoidance — for LQTS, an updated list of QT-prolonging medications (the CredibleMeds list is the standard reference); for Brugada, sodium-channel blockers and fever management.
- An ICD is added when the risk of sudden cardiac death is judged high enough. The threshold differs by condition and by individual risk markers — a survivor of a cardiac arrest gets one; an asymptomatic family member often does not. This is one of the most nuanced decisions in EP.
- Family screening — first-degree relatives should usually be evaluated. This is one of the few moments in medicine where the patient’s care extends naturally to their family.
- Activity counseling — varies by condition. LQT1 patients are usually counseled against competitive swimming. CPVT patients are counseled against intense competitive sport. Brugada activity restrictions are minimal.
Family screening — the most underused tool
If you’ve been diagnosed with one of these conditions, your first-degree relatives — parents, siblings, children — have roughly a 50% chance of also carrying the gene (most are autosomal dominant). The intervention that saves the most lives is screening those relatives with an ECG, a careful history, and (when appropriate) genetic testing. We can often identify carriers years before any symptom emerges, start beta-blockers if indicated, and reduce sudden death risk dramatically.
Bringing relatives in for screening is awkward to ask for and easy to delay. It is also one of the most important things we can do.
What to expect at your visit
A first visit for an inherited arrhythmia question typically covers:
- Detailed personal and family history with a sudden-death family tree if relevant
- Review of all prior ECGs and any monitor data
- Resting 12-lead ECG with careful measurement
- Discussion of whether provocative testing (exercise, ajmaline, genetic) is indicated
- A plan for the patient and a plan for the family
The good news is that with current treatment, most patients with these conditions can live full, normal, long lives. The bad news is that without recognition, the first symptom can be the last. The whole reason this page exists is to make the recognition step happen earlier and more often.